Boston Children's Hospital - Boston, US
OLO’s performance is comparable to analyzers that are 50 times bigger and much more complicated to operate. The ability to take that much analytical power outside of the central lab and bring it to any setting where you can perform a CBC analysis in minutes has huge implications for hospital wards, such as oncology clinics, emergency rooms, neonatal intensive care units, and beyond.
Nicklaus Children's Hospital - Miami, US
To treat children in our urgent care centers, a CBC is essential. OLO represents a major innovation in our laboratories’ CBC analysis: low blood volume (finger-prick) sampling for a five-part differential with flagging. It’s a truly welcome development. At current volumes, we believe OLO could substantially reduce our costs.
University of Cincinnati Medical Center - Ohio, US
OLO makes CBC testing a reality at UC Health. I am impressed with the 5-part diff accuracy and the 10 minutes turnaround time. All it takes is 2 drops of blood in one cuvette, without any wet consumables. Best of all, no calibration or maintenance. It's truly a game changer.
Oldham Integrated Care Centre - Manchester, UK
Thanks to OLO and the use of POC we were able to create a new patient pathway to treat vulnerable non-COVID-19 patients away from the main Oldham hospital. The training we did to learn how to use OLO was straightforward and comprehensive. OLO is an intuitive machine with on-screen step by step instructions which makes the process easy to remember. In addition, the OLO rejects samples that are not properly prepared and explains what went wrong, which helps us learn and improve. OLO also doesn’t require any maintenance, a game changer allowing us more time to care for patients.
Sheba Tel Hashomer Medical Center - Tel Aviv, ISR
The Sight OLO successfully completed a comprehensive evaluation study at the Sheba Tel Hashomer Medical Center. The evaluation compared OLO’s performances to a state-of-the-art analyzer and experienced microscopists, across a wide clinical range. OLO’s excellent performance exceeded predefined acceptance criteria in all aspects. Following the evaluation, we have started a research collaboration with the aim to explore the diagnostic potential of visual signatures in the blood images among different patient populations, including those with COVID-19.